ImmunityBio Misses Q3 2026 Estimates as Revenue Rises 52% to $48.8M

ImmunityBio (IBRX) missed estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $48.8 million, up 52% from a year earlier, below the $59.2 million estimate, and adjusted EPS was -$0.10, down 43% from a year earlier, below the -$0.07 estimate.

Shares fell 13% in premarket trading as of 8:02 a.m. ET, to $7.55 from a $8.63 close.

Q3 2026 scorecard

By our calculation, revenue was $10.4 million below the estimate and adjusted EPS was $0.03 below it. The QoQ column compares with the previous quarter's revenue of $51.2 million and adjusted EPS of -$0.22. The YoY column compares with $32.1 million and -$0.07 in the same quarter a year earlier.

GAAP results

• GAAP EPS. GAAP diluted EPS was -$0.18, against -$0.07 a year earlier.
• Net loss. The company reported a net loss of $184.6 million on a GAAP basis, compared with a net loss of $67.3 million a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 3 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 2 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $32.1 million, $38.3 million, $44.2 million, $51.2 million and $48.8 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$0.07 and revenue of $72.0 million next quarter, based on 2 analysts.
• Next report. ImmunityBio is next expected to report on March 2, 2027.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 52% increase to $48.8 million.
• Related coverage. See our reports on RB Global, Roivant Sciences, Uniti and monday.com.

Sources: Results are from ImmunityBio's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from ImmunityBio's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.